Proving the Business Case for the Internet of Things

ClearSky and Shimmer bring clinical analytics to wearables

Steve Rogerson
July 9, 2019



UK firm ClearSky Medical Diagnostics has forged a partnership with Dublin-based Shimmer Research – a provider of wearable wireless sensing– to bring more analytic capabilities to the use of wearable sensors in clinical research.
 
The partnership will combine Shimmer’s Verisense wearables sensors platform with ClearSky’s algorithms and machine learning expertise to provide insight into central nervous system (CNS) diseases, such as epilepsy or dystonia.
 
Shimmer’s technology and services have been employed by thousands of researchers at more than 900 companies, universities and research institutes in more than 75 countries.
 
Verisense has been designed to meet the needs of clinical trials by capturing accurate and complete biometric data. Worn on the wrist, the Verisense IMU inertial measurement unit sensor can monitor activity and sleep seamlessly. It can also be used for any IMU application with up to seven sensors worn on different parts of a participant’s body.
 
ClearSky specialises in developing technologies for the diagnosis and monitoring of Parkinson’s, Alzheimer’s and other neurodegenerative conditions. Its LID monitor can distinguish Levodopa-induced dyskinesia from Parkinson’s tremors, allowing doctors to optimise Levodopa dosage. It has been supported by Shimmer’s technology.
 
“The Verisense platform is truly a breakthrough for conducting clinical research,” said Stephen Smith, co-founder of ClearSky Medical Diagnostics. “It can provide the continuous raw data from wearables needed for sophisticated algorithms, yet places almost no burden on the participant or the clinical site. It has multiple layers of redundancy and quality checking to ensure that high-quality data are collected without interruption.”
 
The Verisense platform was in action in at last month’s DIA annual meeting in San Diego, California.
 
“ClearSky’s algorithms can be used with Verisense data right away, but what we are really excited about is the potential for our clinical research customers to leverage ClearSky’s experience and datasets to develop endpoints for a wide variety of CNS disorders based on Verisense data,” said Geoff Gill, president of Shimmer Americas. “ClearSky has taken raw motion data and transformed it with machine learning into actionable insights for physicians in a wide range of applications. This experience is ideally suited to develop endpoints for diseases like Parkinson’s, multiple sclerosis, Huntington’s and many others using real-world data.”